ENTX (Entera Bio) Net Margin %: 0.00% (As of Mar. 2026)


ENTX Entera Bio Ltd ENTX
23 GF Score
Price $1.55
! 2 Warning Signs
View Full Analysis

What is Entera Bio Net Margin %?

Entera Bio ENTX 23 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates ENTX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 947 Biotechnology companies, Entera Bio ranks worse than 105596.52% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Entera Bio's Net Income for the three months ended in Mar. 2026 was $-3.51 Mil. Entera Bio's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Entera Bio's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Entera Bio's Net Margin % or its related term are showing as below:


ENTX's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Entera Bio  (NAS:ENTX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Entera Bio Net Margin % Related Terms

Entera Bio Net Margin % Historical Data

* Premium members only.

The historical data trend for Entera Bio's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio Net Margin % Chart

Entera Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,134.33 -9,754.48 0.00 -5,271.27 -27,235.71

Entera Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6,111.90 0.00 0.00 0.00 0.00

ENTX vs IMA, MNOV, ACRV: Net Margin % Comparison

For the Biotechnology subindustry, Entera Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entera Bio Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Net Margin % distribution charts can be found below:

* The bar in red indicates where Entera Bio's Net Margin % falls into.


ENTX
23GF Score
Entera Bio Ltd ENTX
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entera Bio Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Entera Bio's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-11.439/0.042
=-27,235.71 %

Entera Bio's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.505/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Entera Bio (ENTX) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Entera Bio and its competitors. According to the industry distribution chart, Entera Bio ranks #999999 out of 947 companies in the Biotechnology industry.
Is Entera Bio's Net Margin % too high?
Entera Bio's current Net Margin % is 0.00%. Based on the distribution chart, Entera Bio ranks #999999 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Entera Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Entera Bio's Net Margin % compare to IMA and MNOV?
According to the Biotechnology industry distribution chart, Entera Bio ranks #999999 out of 947 companies for Net Margin %. This places Entera Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Entera Bio and its competitors. Entera Bio's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entera Bio stock overvalued right now?
Entera Bio (ENTX) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Entera Bio's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Entera Bio (ENTX), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entera Bio Business Description

Other Exchanges 5DT:Germany
Address Kiryat Hadassah, Minrav Building - Fifth Floor, Hadassah Bio Park, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
23GF Score

Get the complete analysis for ENTX

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price